Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine
12.10.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1.
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer. The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
1 Funding reference number FKZ 13GW0451A+B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RGI Group Strengthens Its Personal Insurance Capabilities in France Through KAPIA-RGI’s Acquisition of Cegid Assurex Solutions7.7.2026 10:30:00 EEST | Press release
RGI, a leading European provider of digital insurance platforms, announces that KAPIA-RGI, its France-based company specialised in personal insurance solutions, has acquired Cegid Assurex solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707323665/en/ This transaction marks a major milestone in the Group's development strategy in French speaking markets in Europe and further enhances its ability to support insurers, mutual insurers, provident institutions, brokers and bancassurers in their innovation and digital transformation initiatives. By integrating Cegid Assurex's expertise, talent and solutions, KAPIA-RGI consolidates its position as the reference leader in the Life Insurance, Savings, Retirement, Annuities and Provident markets. This acquisition expands its client base with more than 20 additional customers while accelerating innovation and growth in a market shaped by evolving regulation, automation and a
Bitcoin Suisse Advances Middle East Expansion, Receiving Financial Services Permission in Abu Dhabi7.7.2026 10:15:00 EEST | Press release
Building on its position as Switzerland’s leading crypto financial services provider, Bitcoin Suisse is further accelerating its international expansion. Bitcoin Suisse Group’s subsidiary, BTCS (Middle East) Ltd. (“BTCS ME”) has received Financial Services Permission (FSP) from the Financial Services Regulatory Authority (FSRA) of ADGM, the international financial centre of Abu Dhabi, marking another significant step toward the Group’s international growth strategy becoming a leading global wealth management partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707864200/en/ Ceyda Majcen, Chief Executive Officer and SEO of BTCS ME, leads Bitcoin Suisse Group's expansion in the Middle East and brings extensive, long-standing senior leadership experience across the Group. The FSP marks the completion of a thorough, multi-stage licensing process and enables BTCS ME to deliver a comprehensive suite of regulated digital asse
Alpaca Completes EEA Passporting to 29 Countries, Expanding Access to Regulated Investment Services Across Europe7.7.2026 10:00:00 EEST | Press release
Alpaca, a global leader in brokerage infrastructure APIs, today announced that it has completed the process to passport its regulated and localized investment services across 29 countries in the EEA (European Economic Area) through its Spain-based EEA hub. The completion of EEA passporting enables Alpaca to extend the regulatory foundation established through its European entity, which is authorized and registered with Spain’s Comisión Nacional del Mercado de Valores (CNMV), across the EEA under the MiFID II framework. Together with Alpaca’s regulated UK entity, this milestone strengthens Alpaca’s ability to support fintechs, financial institutions, and enterprise partners building regulated investment products across Europe, reaching a market of nearly 500 million people. The passported countries include Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania
Capvidia Announces 2026 R1 Software Release to Strengthen MBD Readiness, QIF Workflows, and Digital Thread Automation7.7.2026 10:00:00 EEST | Press release
Capvidia, a provider of Model-Based Definition (MBD), Model-Based Enterprise (MBE), and CAD interoperability software, today announced Capvidia 2026 R1, the latest version of its software portfolio for manufacturers, OEMs, suppliers, and quality organizations. Built with more than 5,600 development hours, Capvidia 2026 R1 includes a combination of over 400 new features, improvements, customer-requested enhancements, and bug fixes across the Capvidia product portfolio. The release helps manufacturers make model-based workflows more practical, validated, and automation-ready. Capvidia 2026 R1 introduces MBDReady Check inside MBDConnect for Creo, expands QIF-based Weld Analysis for Siemens NX, improves Bill of Characteristics and 2D ballooning workflows in MBDVidia, strengthens semantic recognition for machine-readable inspection data, and adds STEP AP242 Edition 3 support. The release supports Capvidia’s focus on True MBD: model-based data that is not only human-readable, but also machin
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release
Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom